Last reviewed · How we verify
Kalimate (calcium polystyrene sulfonate)
Kalimate (generic name: calcium polystyrene sulfonate) is a drug. It is currently in unknown development for Hyperkalemia.
Kalimate works by exchanging potassium ions in the blood for calcium ions.
Kalimate, also known as calcium polystyrene sulfonate, is a small molecule medication used to treat high blood potassium. It is typically given orally or rectally and can cause side effects such as loss of appetite, gastrointestinal upset, constipation, and low blood calcium.
At a glance
| Generic name | calcium polystyrene sulfonate |
|---|---|
| Therapeutic area | Hematology |
| Phase | unknown |
Mechanism of action
Imagine your blood as a bucket with too many balls in it. Kalimate is like a special tool that swaps some of those balls with different ones, making the bucket less crowded and more balanced. This helps to lower the levels of potassium in your blood, which can be dangerous if they get too high.
Approved indications
- Hyperkalemia
Common side effects
- Hyperkalaemia
- Renal impairment
- Cardiac failure
- Crystal deposit intestine
- Shunt stenosis
- Hepatic function abnormal
- Anaemia
- Acute kidney injury
- Interstitial lung disease
- Shunt occlusion
- Chronic kidney disease
- Pneumonia
Key clinical trials
- Osseointegration of THA Grafted by PolyNASS (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®) (NA)
- Comparison of Potassium Binders in the ER (PHASE4)
- Recovery After Dialysis-Requiring Acute Kidney Injury (NA)
- SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients (NA)
- The Effect of Renastart Formula Supplementation in Children With Acute Kidney Injury in Maintaining Normal Serum Electrolytes Levels (NA)
- Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia
- To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder (PHASE1,PHASE2)
- Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kalimate CI brief — competitive landscape report
- Kalimate updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Kalimate
What is Kalimate?
How does Kalimate work?
What is Kalimate used for?
What is the generic name of Kalimate?
What development phase is Kalimate in?
What are the side effects of Kalimate?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Hyperkalemia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing